Latest Headlines

Latest Headlines

Ranbaxy brings in U.S. consultants as part of consent decree

The Indian generics company is bringing in a couple of hired guns to tell it what improvements are left to be made.

Pfizer adds healthy-eating app to Lipitor marketing arsenal

The drugmaker teamed up with EatingWell magazine to develop a mobile app, dubbed Recipes 2 Go, and a sister website, lipitorsmartliving.com. The mobile app hooks into Pfizer's Lipitor co-pay card offer with a feature that makes refills easier.

Rebates cut $40B off drugmakers' returns

In a fascinating look at one aspect of pharma pricing, Forbes' Matthew Herper explores the area of rebates, providing a chart of the biggest givebacks.

With generics horde advancing, Pfizer gives up Lipitor push

When Lipitor's first copycats were unleashed, Pfizer manned the battlements. As The Wall Street Journal reports, that battle is over.

Ranbaxy manufactures a colossal first quarter

Just how important resolving manufacturing problems can be to a drugmaker's upside was evident in the skyrocketing first-quarter earnings of Ranbaxy Laboratories.

Lipitor copy powers a surge in Ranbaxy sales, profits

Ranbaxy Laboratories' first-quarter earnings soared on its launch of the cholesterol drug copycat.

As Lipitor gets more rivals, Lyrica studies fall short

Pfizer's mission to expand Lyrica use just hit a couple of roadblocks.

Pfizer scouts for bite-sized buyouts after Lipitor sales wilt

Followers of Pfizer won't be surprised to learn of Read's M&A appetite, yet the pharma chief happens to be scouting for deals at an interesting time in the industry and at his company.

Abbott tries to throw up roadblock to Humira biosim

The Chicago-based company petitioned the FDA to stop biosimilar versions of Humira, its lead drug, on trade-secret grounds.

Pfizer turns to late-stage pipeline to make up for Lipitor crash

The pharma giant is staying focused on the fate of a trio of late-stage therapies that are desperately needed to fill a growing gap.